Reprint

Drug Delivery Technology Development in Canada

Edited by
December 2019
352 pages
  • ISBN978-3-03928-004-9 (Paperback)
  • ISBN978-3-03928-005-6 (PDF)

This book is a reprint of the Special Issue Drug Delivery Technology Development in Canada that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Canada continues to have a rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community. Over the past 30 years, numerous Canadian-based biotechnology companies have been formed from the inventions conceived and developed within academic institutions that have led to the development of important drug delivery products that have enhanced the landscape of drug therapy in the treatment of cancer to infectious diseases. 

This Special Issue serves to highlight and capture the contemporary progress of drug delivery within the prevailing Canadian context. We invite articles on all aspects of drug delivery sciences from pre-clinical formulation development to human clinical trials that bring to light the world-class research currently undertaken in Canada for this Special Issue.

Format
  • Paperback
License
© 2019 by the authors; CC BY licence
Keywords
doxorubicin; MG63; Vitamin D; DOX-Vit D; hypoxia-induced chemoresistance; cisplatin; polymeric micelle; EGFR-targeted therapy; STAT3; HIF-1; GE11 peptide; pharmacological Inhibitors of HIF-1 and STAT3; combination therapy; pharmacokinetics; antibodies; radiolabeling; biodistribution; mouse models; oral formulation; amphotericin B; fungal infections; parasitic infections; developing world; drug delivery; liposomes; drug delivery systems; innovation; lipid nanoparticles; Metaplex; triggered drug release; liposomes; ultrasound; magnetic fields; radiation; oral delivery; biological barriers; co-delivery; throughput; sustained delivery; phospholipid complex; rosmarinic acid; bioaccessibility; dissolution; TNO gastrointestinal model; gastrointestinal simulator; phytosterols; tocopherols; liposomes; canola oil deodorizer distillate; model orange juice; virus; plant; bacteriophage; phage display; drug discovery; encapsulation; drug delivery; blood-brain barrier; intra-arterial chemotherapy; malignant gliomas; primary central nervous system lymphomas; transdermal drug delivery; Canada; skin; permeation enhancers; oral, head and neck squamous cell carcinoma; targeted therapies; drug delivery systems; nanoparticles; controlled drug delivery; circadian clock; chronotherapy; precision medicine; cationic gemini surfactant; melphalan; inclusion complex; ROESY NMR spectroscopy; 3D spheroid; drug-resistant melanoma; liposome; water miscible solvents; remote loading; staurosporine; cancer; gambogic acid; loading gradients; mefloquine; child friendly formulation; blood-brain barrier (BBB); drug delivery; transient modulation; HAV6 cadherin peptide; adenanthin; magnetic resonance imaging (MRI); medulloblastoma; drug delivery; pharmaceutics; drug development; formulation and dosage form development; translational research; biologicals; small molecules; clinical trials; pharmacokinetics; medical devices; route of administration; nifedipine; emulsion; flavonoids; topical formulation; quercetin; photostabilizers